COMMUNIQUÉ DE PRESSE publié le 01/02/2024 à 13:35, il y a 2 années 6 mois Corporate Update on Clinical Evaluation of MedMira’s Products MedMira Inc. provides update on Health Canada review process for maternity screening, highlighting increasing need due to rising syphilis infection rates. Company's syphilis test performance shows promising results for infectious case detection and maternity screening MedMira Inc. Health Canada Review Maternity Screening Syphilis Infection Rates Test Performance
COMMUNIQUÉ DE PRESSE publié le 30/12/2023 à 05:00, il y a 2 années 7 mois MedMira Reports First Quarter Results FY2024 MedMira Inc. (TSXV:MIR) has reported its financial results for the quarter ended October 31, 2023. The company achieved significant milestones during this period, including receiving US FDA 510(k) clearance for the HIV-2 claim on its Reveal® G4 Rapid HIV 1/2 antibody test. This approval positions MedMira as a key player in the HIV testing market and allows the company to expand its market share and revenue in the United States.
COMMUNIQUÉ DE PRESSE publié le 14/12/2023 à 04:30, il y a 2 années 7 mois U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
COMMUNIQUÉ DE PRESSE publié le 29/11/2023 à 05:00, il y a 2 années 8 mois MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
COMMUNIQUÉ DE PRESSE publié le 28/09/2023 à 04:00, il y a 2 années 10 mois Update on MedMira’s Regulatory Path in Canada and the USA
COMMUNIQUÉ DE PRESSE publié le 31/08/2023 à 04:00, il y a 2 années 11 mois Progress Update on Securities
COMMUNIQUÉ DE PRESSE publié le 30/06/2023 à 04:00, il y a 3 années 1 mois MedMira Reports Third Quarter Results FY2023
COMMUNIQUÉ DE PRESSE publié le 04/04/2023 à 03:00, il y a 3 années 4 mois MedMira Reports Second Quarter Results FY2023
COMMUNIQUÉ DE PRESSE publié le 14/03/2023 à 21:31, il y a 3 années 4 mois Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada
COMMUNIQUÉ DE PRESSE publié le 20/02/2023 à 23:00, il y a 3 années 5 mois MedMira Enters into Partnership with Maternova for USA and Latin America
Publié le 10/08/2026 à 18:00, il y a 4 heures 2 minutes AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Publié le 10/08/2026 à 18:00, il y a 4 heures 2 minutes AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Publié le 10/08/2026 à 17:45, il y a 4 heures 17 minutes Déclaration hebdomadaire de rachat d'actions
Publié le 10/08/2026 à 11:53, il y a 10 heures 9 minutes GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Publié le 10/08/2026 à 21:35, il y a 27 minutes Sekur Private Data Government Team Attending DoDIIS Worldwide Intelligence Conference
Publié le 10/08/2026 à 20:30, il y a 1 heure 32 minutes Clean Air Metals and Fiore-backed Springbok Ventures Announce Upsize of Non-Brokered Private Placement
Publié le 10/08/2026 à 15:30, il y a 6 heures 32 minutes Silver Spruce Resources, Inc. Announces New Chief Financial Officer
Publié le 10/08/2026 à 15:25, il y a 6 heures 37 minutes Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Publié le 10/08/2026 à 14:30, il y a 7 heures 32 minutes NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Publié le 10/08/2026 à 20:24, il y a 1 heure 38 minutes EQS-Adhoc: PNE AG updates on ongoing sales process
Publié le 10/08/2026 à 19:35, il y a 2 heures 27 minutes Kontron AG: All conditions of the mandatory tender offer of Ennoconn Corporation are met – Settlement will take place shortly
Publié le 10/08/2026 à 19:00, il y a 3 heures 2 minutes PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 03 AOUT 2026 au 07 AOUT 2026
Publié le 10/08/2026 à 18:29, il y a 3 heures 33 minutes Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Publié le 10/08/2026 à 17:50, il y a 4 heures 12 minutes Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 1st Interim Report